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A B S T R A C TObjectives: The long-term cost effectiveness of routine HIV testing is
favorable relative to other medical interventions. Facility-specific
costs of expanded HIV testing and care for newly identified patients,
however, are less well defined. To aid in resource allocation decisions,
we developed a spreadsheet-based budget-impact tool populated with
estimates of facility-specific HIV testing and care costs incurred with
an expanded testing program. Methods: We modeled intervention
effects on quarterly costs of antiretroviral therapy (ART), outpatient
resource utilization, and staff expenditures in the Department of
Veterans Affairs over a 2-year period of increasing HIV testing rates.
We used HIV prevalence estimates, screening rates, counseling,
positive tests, Veterans Affairs treatment, and published sources as
inputs. We evaluated a single-facility cohort of 20,000 patients and at
baseline assumed a serodiagnostic rate of 0.45%. Results: Expanding
testing from 2% to 15% annually identified 21 additional HIV-positive
patients over 2 years at a cost of approximately $290,000, more thannt matter Copyright & 2012, International Society
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73.60% of which was due to providing ART to newly diagnosed patients.
While quarterly testing costs decreased longitudinally as fewer
persons required testing, quarterly ART costs increased from $10,000
to more than $60,000 over 2 years as more infected patients were
identified and started on ART. In sensitivity analyses, serodiagnostic
and annual HIV testing rates had the greatest cost impact. Conclu-
sions: Expanded HIV testing costs are greatest during initial imple-
mentation and predominantly due to ART for new patients. Cost
determinations of expanded HIV testing provide an important tool for
managers charged with allocating resources within integrated sys-
tems providing both HIV testing and care.
Keywords: budget impact analysis, cost-effectiveness, facility costs,
HIV testing.
Copyright & 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Early diagnosis of HIV infection allows for the timely initiation of
highly effective, life-prolonging antiretroviral therapy (ART). The
impact of early treatment and its cost-effectiveness have led the
Centers for Disease Control and Prevention to recommend uni-
versal HIV testing (otherwise known as routine or non–risk-based
testing) for all persons between the ages of 13 to 64 years in
populations in which the prevalence of HIV infection exceeds
0.1% while others recommend offering tests to all adults [1–5].
Because most individuals interact routinely with primary care
physicians, programs to increase universal HIV testing rates
are most appropriately initiated in the primary care setting.
Unfortunately, opportunities for HIV testing during routinemedical care are often missed by providers, or passed over by
patients. As a consequence, many HIV-positive patients are
identified and diagnosed later in the disease course than is
optimal [6,7].
While early recognition and therapy for HIV infection is cost-
effective for patient populations with a greater than 0.1% pre-
valence of undiagnosed infection, it is not costsaving. The Robert
Wood Johnson Foundation [8] has expressed this distinction as
follows:
‘‘Cost-saving’’ and ‘‘cost-effective’’ are distinct terms that are
often mistakenly used interchangeably. Preventive care that
decreases costs is cost-saving (e.g., many childhood immuniza-
tions). If the benefits are sufficiently large compared to thefor Pharmacoeconomics and Outcomes Research (ISPOR).
sis, Prevention, and Access to Care, Washington, DC; 2008 Quality
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VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 0 2 2 – 1 0 2 8 1023costs, the intervention is ‘‘cost-effective’’ even if it does not
save money.
Previous studies have found that the implementation of
routine, once-per lifetime HIV testing increased the lifetime cost
of care for an individual HIV-infected patient by $333 to $2600
[1,2]. Furthermore, the health benefits of routine HIV testing to
identify patients with asymptomatic infection accrue over many
years, while the costs of testing and managing newly identified
patients arise immediately. This mismatch between the imme-
diacy of facility-specific costs of program implementation and
the delayed benefits, which may accrue after the patient has
changed health care providers, can provide a disincentive for
managers in health care systems with incomplete longitudinal
care, as is the case in the United States, to implement HIV testing
programs in the face of short-term budget time frames and
competing resource demands [9].
In this study, we estimated the facility-level budget impact of
increasing HIV testing rates and providing ART to newly diag-
nosed patients in US Veterans Healthcare Administration (VHA)
facilities. This analysis benefited from data collected during the
implementation of a program to promote HIV testing in the VHA
that demonstrated a sustainable doubling to tripling of HIV
testing rates in primary care clinics [10,11]. Previous budget
impact analyses of the costs of implementing HIV testing pro-
grams in the United States have taken a societal perspective and
excluded HIV-infected patients receiving care in the VHA [12].
This work, by contrast, focuses on the costs borne by integrated
health care systems that both offer HIV testing and provide
HIV care.Methods
Construction of the Budget Impact Model
We constructed a spreadsheet-based budget impact analysis
model. We estimated facility costs for HIV testing in a primary
care setting, including the costs of pretest counseling, HIV testing
rates and treatment of identified HIV-infected patients, (e.g., the
need for increased MD full-time equivalent positions, increased
pharmacy purchases of antiretroviral agents, and laboratory
costs of monitoring the effectiveness of such therapy). We chose
to evaluate facility costs quarterly. We did not include the costs of
routine primary care or of institutional reorganization to promote
HIV testing. To provide a broader context for the costs of HIV
testing, we also estimated the costs of ongoing ART and monitor-
ing for previously identified HIV-infected patients.
Data Collection
To refine the model, we solicited expert opinion from two
Veterans Affairs (VA) HIV providers (an infectious disease/HIV
specialist and a general internist with specific interest in HIV/
AIDS identification and care) to determine the model end points
of interest. We selected the following end points: physician and
nurse staffing costs, laboratory costs, and costs of ART associated
with differing levels of HIV disease progression as calculated by
CD4 count. The model was dynamic and considered quarter-to-
quarter changes in patient status (i.e., changes in CD4þ cell
count), loss to follow-up, and mortality. Figure 1 provides an
overview of the flow of patients through the three phrases of HIV
care: screening, diagnostics, and management.
The model can be envisioned as a quarter-to-quarter flow-
chart designed to calculate the costs associated with both tested
and untested patients of known and unknown HIV status
receiving care at a single medical facility over eight 3-month
periods (quarters). In our model, we assumed that primary carenurses were responsible for offering and ordering HIV tests.
Baseline case variables and ranges used in the spreadsheet
models are presented in Table 1.
Model Description
We first estimated the proportion of patients (screened and
unscreened for HIV) on the basis of data from our previous work
[10]. We then assembled a hypothetical annual cohort of 20,000
adult patients, of whom 9.2% had previously been tested for HIV
with the added assumption of a 2.1% annual baseline rate of HIV
testing in previously untested patients. We assumed that 200
patients were already known to be HIV infected and were
receiving care. By using the inputs shown in Table 1, the model
estimated the number of patients in each quarter who would be
tested for HIV, the number who would be found to be infected,
the distribution of newly diagnosed patients in different clinical
strata (i.e., with 4500 CD4þ cells/mL, with 350 to 500 CD4þ cells/
mL, with between 200 and 350 CD4þ cells/mL, and, finally, with
fewer than 200 CD4þ cells/mL), and the proportion of newly
diagnosed patients in each stratumwho started ART. The number
and characteristics of newly diagnosed patients in each strata
were used to calculate the quarterly costs of patient care and ART
for these individuals.Results
We first assessed the costs of maintaining a low, baseline 2.1%
annual rate of HIV testing (Fig. 2); costs are separated into those
that are related to HIV diagnostic testing and the care of persons
newly identified as HIV infected versus costs related to the care of
patients previously identified as being HIV infected.
Our model shows that the costs of maintaining this baseline
HIV testing program is a small proportion of the total costs of the
HIV care program, as the mean quarterly laboratory, personnel,
and pharmacy costs were $1,400 versus $33,000, $1,300 versus
$61,000, and $6,404 versus $647,000 comparing the testing pro-
gram with the care program for previously identified patients,
respectively. Notably, pharmaceutical expenditures for ART of
patients entering care accounts for 71% of the costs of the testing
program. While the personnel costs for nursing involvement in
primary care clinics and laboratory costs due to HIV diagnostic
testing per se gradually decrease as the pool of previously
untested patients diminishes over time, overall personnel,
laboratory, and pharmacy costs attributed to the testing program
increase as more HIV-infected patients enter care and require
subspecialty clinical services, specialized laboratory monitoring,
and ART.
We next assessed the costs associated with increasing the rate
of HIV testing (Fig. 3). By increasing the testing rate from a
baseline of 2.1% to 15%, the model inputs predict that the facility
would incur an additional cost of approximately $290,000 over a
2-year period (right panel, Fig. 3), of which $73,000 (25%) is
attributable to the cost of testing per se (left panel, Fig. 3). The
overall increase is largely due to pharmaceutical expenditures for
ART and is thus highly sensitive to the distribution of advanced
disease among newly identified patients and to the consequent
rate at which ART is initiated. As shown in Figure 3, the costs of
the expanded HIV testing program per se peak at approximately
$10,000 in the first quarter of program implementation. In
contrast, the marginal cost of caring for newly identified patients
steadily increases over time, reaching more than $50,000 in the
eighth quarter of increased testing. This trend reflects increases
in the aggregate number of newly diagnosed patients receiving
ART. Over the course of 2 years, our base-case conditions indicate
that whereas 3 patients would be newly diagnosed with a testing
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Fig. 1 – Decision tree model of three phases of HIV care: screening, diagnostics, and treatment management. A decision-
analytic model of all the possible typical stages of a patient entering the primary care unit at Veterans Affairs Healthcare
System for HIV screening is illustrated. Personnel and direct material cost associated with administrating the HIV screening,
testing, and treating patients positively identified with HIV will be measured in three phases: screening phase, diagnostic
phase, and treatment management.
VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 0 2 2 – 1 0 2 81024rate of 2.1%, 24 patients would be newly diagnosed by instituting
an annual testing rate of 15%.Sensitivity Analysis
To both evaluate the robustness of our baseline case values and
to aid managers making implementation decisions, we con-
ducted a series of sensitivity analyses based on the values listed
in Table 1. For our base case, we used values derived from studies
and analyses of data from VA health care facilities [10,13,14].
These included a preintervention HIV testing rate of 2.1% per
year, a postintervention test rate of 15% per year, a 9.2%
prevalence of known prior HIV testing, a 0.45% HIV serodiagnosis
rate, and 3 minutes of nursing time to explain the rationale for
HIV testing, obtain verbal consent for testing, and order the test.
For our sensitivity analysis, we considered the effect of separately
altering each of these variables on the marginal increase in
pharmacy, personnel, and laboratory costs over the 2-year period
of interest.
As shown in Figure 4, for a postintervention test rate of
30% rather than 15%, the aggregate 2-year pharmaceutical,
personnel, and laboratory costs of the program increased from
approximately $290,000 (base case) to $580,000. Similar large
increases (to nearly $575,000) were found if the prevalence of
HIV infection among tested patients was estimated to be 1.0%rather than 0.45%. As in the base-case analyses, pharmaceutical
costs for ARTaccounted for more than 60% of all costs in all cases
except when the HIV prevalence was assumed to be 0.1%, in
which case pharmaceutical costs accounted for 42% of all
increased expenditures. Within the examined bounds, the costs
of the HIV testing program were relatively insensitive to changes
in the time nurses devoted to obtaining verbal consent and
ordering tests, or in the proportion of patients previously tested
for HIV.Discussion
The mismatch between the well-established delayed benefits of
HIV testing and care versus the immediate costs of HIV testing
and care provides a potential disincentive for investing in
enhanced HIV testing programs. In this article, we performed a
budget impact analysis to estimate the costs of increasing HIV
testing. This provides a framework that health care managers
can use in making resource allocation decisions related to HIV
testing. This analysis, which used VHA-specific inputs derived in
part from our previous work demonstrating the sustainable two-
to threefold increase in HIV testing [10.11], showed that an even
greater increase in HIV testing, that is, from 2.1% to 15% annually,
is accompanied by an initial facility-level cost of $10,000 per
quarter that steadily increases to more than $60,000 per quarter
Table 1 – Variables and ranges used.
HIV testing rate Base case Range of results Reference source
Baseline yearly screening rate (%)* 2.1 (0.3–5.7) [10,11,13]
Enhanced yearly screening rate (%) 15 (4–30) [10,13,15]
Baseline prevalent screening (%) 9.2 (5.6–20) [11]
Positive rate (%) 0.45 (0.1–1.0) [14]
Baseline HIVþ patients 200 Assumed
Distribution of CD4 counts of existing patients
CD44 500 (%) 39 77 GLA data†
CD4 350–499 (%) 24 49 GLA data
CD4 200–349 (%) 23 45 GLA data
CD4o 200 (%) 14 29 GLA data
Distribution of CD4 counts at time of new diagnosis
CD44 500 (%) 29 [13]
CD4 350–499 (%) 21 [13]
CD4 200–349 (%) 20 [13]
CD4o 200 (%) 30 [13]
Use of ART in existing patients
Current CD44 500 cells/mL (%) 84 GLA data
Current CD4 350–499 cells/mL (%) 84 GLA data
Current CD4 200–349 cells/mL (%) 88 GLA data
Current CD4o 200 cells/mL (%) 87 GLA data
Start of ARTwithin 90 d in new patients
Current CD44 500 cells/mL (%) 8 [13]
Current CD4 350–499 cells/mL (%) 27 [13]
Current CD4 200–349 cells/mL (%) 47 [13]
Current CD4o 200 cells/mL (%) 68 [13]
Patients remaining on ART per quarter
Current CD44 500 cells/mL (%) 95 [13]
Current CD4 350–499 cells/mL (%) 95 [13]
Current CD4 200–349 cells/mL (%) 95 [13]
Current CD4o 200 cells/mL (%) 95 [13]
Change in CD4 strata per quarter
% dropping to lower strata without therapy 5
% increasing to higher strata with therapy 5
Costs of ART per quarter ($)
CD44 500 cells/mL 3439.80 VA Pharmacy data
CD4 350–499 cells/mL 3506.45 VA Pharmacy data
CD4 200–349 cells/mL 3689.65 VA Pharmacy data
CD4o 200 cells/mL 3872.85 VA Pharmacy data
Costs and infrastructure per patient per quarter
Personnel costs
Physician assistant (1 per 200 HIV-infected patients) 0.005 GLA data
ID attendings (1 per 400 HIV-infected patients) 0.0025 GLA data
Pretest nursing time (min) 3 (1–5) [13]
Posttest () counseling time (min) primary care physician 2 (1–4) [13]
Posttest (þ) counseling time (min) primary care physician 25 (18–30) [13]
Laboratory costs ($)
CD4 cell count (one per quarter) 55.00 GLA data
HIV-1 RNA quantitation (one per quarter) 110.00 GLA data
HIV laboratory testing per new patient 585.00 [17]†
Cost of screening test (EIA) 8.00 GLA data
Cost of confirmatory test (immunoblot) 45.00 GLA data
Personnel costs (with 30% benefits) ($)
Infectious diseases physician assistant 121,128 GLA data
Infectious diseases physician 247,000 GLA data
Primary care registered nurse 84,279 GLA data
Primary care physician 198,073 GLA data
ART, antiretroviral therapy; ID, infectious disease; VA, Veterans Affairs.
* Note that quarterly data are used in the models.
† Data from VA Greater Los Angeles Healthcare System.
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Fig. 2 – Cost of testing and medical care of previously identified HIV-infected patients’ maintenance of 2.1% annual testing
rate. The figure shows the cost of sustaining the baseline HIV testing program in which 2.1% of previously untested patients
undergo HIV testing each year as well as the costs of caring for patients identified as being HIV infected prior to quarter 1.
The left-hand panel includes the cost of the testing program per se as well as the costs for outpatient personnel, laboratory
monitoring, and antiretroviral agents for persons newly found to be HIV infected during the eight quarters of testing. The
right-hand panel provides the costs for outpatient personnel, laboratory monitoring, and antiretroviral agents previously
identified as being HIV infected and receiving care.
VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 0 2 2 – 1 0 2 81026at the end of 2 years. This cost is relatively modest compared
with the budget of the average VHA facility, which is well over
$300 million per year. In our base-case conditions, this increase
in testing would result in an additional 21 patients being
identified as being HIV infected. If only the costs of HIV testing
per se are considered, an enhanced HIV testing program that
results in 21 additional diagnoses is predicted to cost less than
$80,000 over a 2-year period. In health care systems that provide
both HIV testing and HIV care, however, it is the cost of caring for
these newly identified patients that accounts for more than 60%
of the costs of enhanced testing. Thus, in our base case, while the
cost of HIV testing was less than $80,000 over a 2-year period, the
cost of ART for newly infected patients was more than $200,000.
We augmented our base-case analysis by sensitivity analyses
that assessed the effect of increasing the HIV testing rate from
15% to 30%, the rate of positive tests from 0.45% to 1%, and
nursing time for pretest activities from 3 to 5 minutes. Because of
detecting a greater number of infected patients and starting suchFig. 3 – Marginal increase in costs of HIV testing and care of new
the projected marginal quarterly increases in laboratory and pe
and the laboratory, personnel, and antiretroviral costs of caring
annual rate of testing previously untested patients is increasedindividuals on ART, increases in the HIV testing rate from 15% to
30% or in HIV seropositivity from 0.45% to 1.0% showed a twofold
cost increase ( $300,000) compared with baseline. In contrast,
changes in the time allocated for nurse-based pretest counseling
or in the proportion of patients previously tested for HIV had
relatively little impact on cost.
Our findings indicate that recommendations to routinely offer
HIV testing to all adults aged 13 to 64 years, as per the Centers for
Disease Control and Prevention [3], or to all adults regardless of
age, as per the American College of Physicians [4] and the
Veterans Health Administration [5], is not only cost-effective
using a $50,000 per quality-adjusted life-year threshold [1,2] but
also within reasonable cost bounds, with a total cost of $80,000
over 2 years for testing per se and $290,000 for testing and
subsequent care of the 21 additional HIV-infected patients iden-
tified in our base-case model. As such, these results are of value
to health care managers who need to plan for the additional
organizational costs during the initial implementation andly identified patients with HIV infection. The figure presents
rsonnel costs of the HIV testing program (left-hand panel)
for persons newly identified as being HIV infected when the
from 2.1% to 15%.
Fig. 4 – Aggregate increased cost over eight quarters with expansion of HIV testing under varying conditions. The base case
used a prior HIV testing rate of 2.1% per year, a postintervention test rate of 15% per year, assumed that 9.2% of the patients
had been previously tested for HIV infection, that 0.45% of all tests represented true positive tests, and that nurses spent 3
minutes explaining the rationale for HIV testing and obtaining verbal consent for testing to be done. Other conditions vary
as indicated in the figure. Total pharmacy costs were $375,000 (off scale). yTotal pharmacy costs were $407,000 (off scale).
VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 0 2 2 – 1 0 2 8 1027postintervention phases of expanded HIV testing and treatment
programs [1].
Budget impact analyses complement cost-effectiveness ana-
lyses and implementation-based trials. The latter provide neces-
sary but not sufficient evidence for the large-scale dissemination
of clinical interventions. In contrast, budget impact analyses can
help inform decision makers regarding the short-term costs of
implementing a specific intervention. The ability to categorize
and highlight the sources of organizational costs, which many
times occur across internal organizational boundaries, is crucial
to convince internal stakeholders to participate in new large-
scale projects. Budget impact evaluations are most useful in
integrated systems such as the VA, where trade-offs between
internal stakeholders that involve long-term and short-term
outcomes are more easily made than when the financial impacts
have disparate effects on organizationally independent entities
that are not as intricately bound to one another financially [12].
In the work presented here, we followed the guidelines put
forth (with some modification) by the International Society
of Pharamacoeconomic and Outcomes Research Task Force.
Because our core objective was to present a feasible and adap-
table framework for health care managers to adopt and modify,
we chose a simple-to-use spreadsheet model to perform this
budget impact analysis. An important aspect of this planning tool
is its flexibility, which allows for customization of inputs to
accommodate different cost structures, clinical practices, and
patient populations at differing VA and non-VA facilities. An
alternative approach would have been to use a deterministic
Markov model that considers the natural history of HIV patients,
which could then be used to address budget impact analysis.Limitations
Our analysis considers facility-specific costs over a relatively
short 2-year period. This choice was purposely made because
our goal was to evaluate the initial impact of implementing
expanded HIV testing programs. We also assumed that the
patient population remained constant over this 2-year interval
whereas approximately 20% of patients enrolled in VA health
care do not utilize the system in a given year [15]. To the degree
that this loss to follow-up occurs for patients identified as being
HIV infected, however, this would reduce the global costs of an
HIV testing program by reducing ART expenditures.Nevertheless, the 2-year analysis still informs decisions
regarding the allocation of resources within integrated health
care facilities that provide both HIV testing and care and
complements other analyses of the long-term individual and
societal costs of expanded HIV testing and earlier initiation of
ART [12,16]. In addition, although a yearly rate of HIV testing of
15% to 30% might be criticized as being low, this is similar to rates
that have been considered reasonably achievable and appropriate
by others [12]. Finally, while our analysis relied heavily on VA-
specific data, the overall findings are likely to be relevant to other
health care systems with a fixed global budgeting structure and
with longitudinal patient follow-up [17].Conclusions
Translating clinical research into real-world improvements is a
challenge for all health care systems especially when the inter-
vention is not costsaving and the clinical benefits of the inter-
vention are delayed. Expanded HIV testing is no exception. It has
demonstrated downstream positive effects on health, but first
health care systems must be transformed to provide routine
testing reliably. This budget impact analysis indicates that the
costs of such a program are not formidable. We found that in an
integrated care system, an increase in HIV testing from 2.1% to
15% annually is accompanied by a relatively modest initial
facility-level cost of $10,000 per quarter that increases to more
than $60,000 per quarter at the end of 2 years because of the cost
of providing ART to persons entering care for newly identified
HIV infection. For programs that only offer testing to a fixed
patient population, the costs of testing decrease over time as the
number of untested people decreases.Acknowledgments
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